GetTopicDetailResponse(id=78aa659917b, topicName=淋巴細(xì)胞亞群, introduction=淋巴細(xì)胞亞群, content=null, image=null, comments=1, allHits=1349, url=https://h5.medsci.cn/topic?id=65991, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=35206, tagList=[TagDto(tagId=35206, tagName=淋巴細(xì)胞亞群)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2234228, encodeId=1243223422867, content=<a href='/topic/show?id=78aa659917b' target=_blank style='color:#2F92EE;'>#淋巴細(xì)胞亞群#</a> 隨著老腎移植術(shù)后年患者的數(shù)量逐漸增加，研究表明他們術(shù)后感染和惡性腫瘤的發(fā)生率顯著高于年輕患者，盡管急性排斥反應(yīng)的發(fā)生率較低?，F(xiàn)有的免疫抑制方案多為統(tǒng)一標(biāo)準(zhǔn)，未考慮年齡差異。然而，老年患者對(duì)免疫抑制藥物的代謝能力下降，且過度抑制可能導(dǎo)致感染和腫瘤風(fēng)險(xiǎn)增加。因此，優(yōu)化老年腎移植患者的免疫抑制治療方案，特別是在不增加排斥反應(yīng)風(fēng)險(xiǎn)的前提下減少藥物相關(guān)并發(fā)癥，成為亟需解決的臨床問題。本研究旨在評(píng)估老年腎移植患者在兔抗胸腺細(xì)胞球蛋白（rATG）誘導(dǎo)后，早期將霉酚酸鈉（MPS）轉(zhuǎn)換為依維莫司（EVL）的效果，尤其是其對(duì)外周血T淋巴細(xì)胞亞群的影響。, objectTitle=淋巴細(xì)胞亞群, objectType=topic, longId=65991, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=0, createdTime=2024-10-31, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2233871, encodeId=c93822338e1f3, content=<a href='/topic/show?id=00b68262e91' target=_blank style='color:#2F92EE;'>#腎移植術(shù)后#</a> <a href='/topic/show?id=78aa659917b' target=_blank style='color:#2F92EE;'>#淋巴細(xì)胞亞群#</a>, objectTitle=Front Immunol：老年腎移植患者早期免疫抑制治療轉(zhuǎn)換對(duì)淋巴細(xì)胞亞群的影響, objectType=article, longId=848589, objectId=18f68485890f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401024/1729733317694_8538692.png, objectUrl=/article/show_article.do?id=18f68485890f, replyNumber=0, likeNumber=40, createdTime=2024-10-29, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=18f68485890f, moduleTitle=Front Immunol：老年腎移植患者早期免疫抑制治療轉(zhuǎn)換對(duì)淋巴細(xì)胞亞群的影響, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=18f68485890f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2187611, encodeId=8ac7218e611f6, content=<a href='/topic/show?id=fcac3e0290c' target=_blank style='color:#2F92EE;'>#原發(fā)免疫性血小板減少癥#</a> <a href='/topic/show?id=78aa659917b' target=_blank style='color:#2F92EE;'>#淋巴細(xì)胞亞群#</a>, objectTitle=Hematology：淋巴細(xì)胞亞群是免疫血小板減少癥患者反應(yīng)的潛在預(yù)測(cè)因子, objectType=article, longId=813523, objectId=872e813523a2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221120/1669014368634_4754896.webp, objectUrl=/article/show_article.do?id=872e813523a2, replyNumber=0, likeNumber=131, createdTime=2024-02-16, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=872e813523a2, moduleTitle=Hematology：淋巴細(xì)胞亞群是免疫血小板減少癥患者反應(yīng)的潛在預(yù)測(cè)因子, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=872e813523a2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2173520, encodeId=9c2c21e352023, content=<a href='/topic/show?id=d536e14259d' target=_blank style='color:#2F92EE;'>#癌癥疫苗#</a> <a href='/topic/show?id=78aa659917b' target=_blank style='color:#2F92EE;'>#淋巴細(xì)胞亞群#</a>, objectTitle=前沿進(jìn)展 | 激活淋巴細(xì)胞亞群：新型癌癥疫苗有望成為腫瘤終結(jié)者, objectType=article, longId=803902, objectId=f7a7803902f1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894174714_4754896.jpeg, objectUrl=/article/show_article.do?id=f7a7803902f1, replyNumber=0, likeNumber=133, createdTime=2023-12-07, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f7a7803902f1, moduleTitle=前沿進(jìn)展 | 激活淋巴細(xì)胞亞群：新型癌癥疫苗有望成為腫瘤終結(jié)者, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f7a7803902f1)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯話題小助手
2020-05-29
前往app查看評(píng)論內(nèi)容
#淋巴細(xì)胞亞群# 隨著老腎移植術(shù)后年患者的數(shù)量逐漸增加，研究表明他們術(shù)后感染和惡性腫瘤的發(fā)生率顯著高于年輕患者，盡管急性排斥反應(yīng)的發(fā)生率較低?，F(xiàn)有的免疫抑制方案多為統(tǒng)一標(biāo)準(zhǔn)，未考慮年齡差異。然而，老年患者對(duì)免疫抑制藥物的代謝能力下降，且過度抑制可能導(dǎo)致感染和腫瘤風(fēng)險(xiǎn)增加。因此，優(yōu)化老年腎移植患者的免疫抑制治療方案，特別是在不增加排斥反應(yīng)風(fēng)險(xiǎn)的前提下減少藥物相關(guān)并發(fā)癥，成為亟需解決的臨床問題。本研究旨在評(píng)估老年腎移植患者在兔抗胸腺細(xì)胞球蛋白（rATG）誘導(dǎo)后，早期將霉酚酸鈉（MPS）轉(zhuǎn)換為依維莫司（EVL）的效果，尤其是其對(duì)外周血T淋巴細(xì)胞亞群的影響。
